NATCOPHARM vs VENUSREM: Stock Comparison
NATCO PHARMA is the larger company by market capitalisation. NATCO PHARMA shows a lower P/E and a higher net margin, while VENUSREM shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
NATCOPHARM leads 4; VENUSREM leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | NATCOPHARM | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | NATCOPHARM | VENUSREM |
|---|---|---|
| Live Price | ₹795.4 | ₹1,796.7 |
| Day Change | -1.81% | 0.03% |
| Volume | 3.12 L | 1.17 L |
| 52-Week High | ₹1,226.8 | ₹1,880 |
| 52-Week Low | ₹792.05 | ₹432.1 |
| Distance from 52W High | -35.16% | -4.43% |
Valuation
| Metric | NATCOPHARM | VENUSREM |
|---|---|---|
| Market Cap | ₹14,257 Cr | ₹2,233 Cr |
| P/E Ratio | 12.46x | 19.22x |
| P/B Ratio | 1.55x | 3.36x |
| EPS | ₹4.17 | ₹19.1 |
| Book Value | ₹514.83 | ₹496.56 |
| Dividend Yield | 0.55% | 0.56% |
Growth
| Metric | NATCOPHARM | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | -39.6% | 33% |
| EPS Growth (TTM YoY) | -34.1% | 126.4% |
| Qtr Sales Growth | -18.85% | -0.03% |
| Qtr Profit Growth | -63.87% | 11.14% |
Profitability & Leverage
| Metric | NATCOPHARM | VENUSREM |
|---|---|---|
| ROE | 14.98% | 15.49% |
| ROCE | 14.19% | 16.2% |
| Net Margin | 34.78% | 13.35% |
| Operating Margin | 38.85% | 17.56% |
| Debt to Equity | 0.08x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | NATCOPHARM | VENUSREM |
|---|---|---|
| Promoter Holding | 49.14% | 41.76% |
| FII Holding | 16.99%▼ 0.38 pp | 2.92%▲ 0.12 pp |
| DII Holding | 5.62%▲ 0.16 pp | 0.89%▼ 0.31 pp |
| Public Holding | 27.97%▲ 0.22 pp | 54.43%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NATCO PHARMA and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.